Vericel (VCEL) Asset Writedowns and Impairment (2014 - 2026)

Vericel (VCEL) reported Asset Writedowns and Impairment of $173000.0 for Q1 2026, up 157.1% sequentially from -$303000.0 in Q4 2018.

Vericel (VCEL) Asset Writedowns and Impairment (2014 - 2026) Analysis & Trends

Vericel (VCEL) has 6 years of Asset Writedowns and Impairment data on file, last reported at $173000.0 in Q1 2026.

For the quarter ending Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $173000.0; the trailing twelve-month figure through Mar 2026 stood at $407000.0 (up 332.98% YoY), and the FY2025 full-year result was $1.0 million, changed N/A from the prior year.
Asset Writedowns and Impairment climbed to $173000.0 in Q1 2026, from -$303000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $173000.0 in Q1 2026 to a low of $173000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Vericel	2.30 Bn	2.15 Bn	49.27 Mn

Download Data